Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Current Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Total Current Liabilities for 16 consecutive years, with $15.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 43.27% to $15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, up 43.27% year-over-year, with the annual reading at $15.0 million for FY2025, 43.27% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $15.0 million at Altimmune, up from $12.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $19.1 million in Q3 2021, with the low at $8.6 million in Q3 2024.
  • Average Total Current Liabilities over 5 years is $13.2 million, with a median of $12.4 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 203.91% in 2021, then crashed 39.16% in 2025.
  • Over 5 years, Total Current Liabilities stood at $18.3 million in 2021, then decreased by 6.69% to $17.1 million in 2022, then dropped by 28.8% to $12.1 million in 2023, then dropped by 13.79% to $10.5 million in 2024, then surged by 43.27% to $15.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $15.0 million, $12.6 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.